Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE 14 6.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus SODIUM CHLORIDE 14 6.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs SODIUM CHLORIDE 14.6%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Sodium chloride 14.6% is a hypertonic saline solution that increases serum osmolality, drawing water from the intracellular space into the extracellular compartment, thereby reducing cerebral edema and intracranial pressure. It also acts as a volume expander and electrolyte replenisher.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion via central line; typical dose for severe hyponatremia is 100-150 mL over 20 minutes (150 mL max) for acute correction, then 0.5-1 mmol/L/hour increase not exceeding 8 mmol/L in 24 hours.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Not applicable; sodium and chloride ions are homeostatically regulated with no defined terminal half-life. Rapidly redistributed and excreted, with clinical effect related to plasma concentration.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Renal: >90% as unchanged sodium and chloride ions; minor fecal (<5%) and negligible biliary elimination.
Category C
Category A/B
Electrolyte
Electrolyte